MINNEAPOLIS, Sept. 10 /PRNewswire/ -- Exsulin Corporation today announced the
start of a phase II human clinical trial of Exsulin(TM), a peptide drug
product aimed at restoring insulin production in people with diabetes
mellitus. The randomized, controlled 12-week trial in patients with
established Type 1 diabetes (T1DM) will be co-led by Mayo Clinic in Rochester,
Minn., and McGill University Health Centre in Montreal, Canada. First results
are expected to be available in Q2 2010. The design of the study is based on
previous trials which showed improvement in insulin secretion and glucose
control in both Type 1 and Type 2 diabetes (T2DM) patients treated with
Exsulin.
